These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 7318837

  • 1. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, De Virgiliis S, Cao A.
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [Abstract] [Full Text] [Related]

  • 2. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S, Cossu P, Sanna G, Frau F, Loi E, Lobrano R, Nucaro A, Toccafondi C, Cornacchia G, Loi A, Cao A.
    Acta Haematol; 1982 Nov; 67(1):49-56. PubMed ID: 6800202
    [Abstract] [Full Text] [Related]

  • 3. Early iron overload in beta-thalassaemia major: when to start chelation therapy?
    Fargion S, Taddei MT, Gabutti V, Piga A, Di Palma A, Capra L, Fontanelli G, Avanzini A.
    Arch Dis Child; 1982 Dec; 57(12):929-33. PubMed ID: 7181522
    [Abstract] [Full Text] [Related]

  • 4. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP, Kumar S, Choudhury P, Talukdar B, Puri RK.
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [Abstract] [Full Text] [Related]

  • 5. [Evaluation of iron overload in thalassemia].
    Piga A, Davico S, Magliano M, Luzzatto L, Sandri A, Gabutti V.
    Pediatr Med Chir; 1986 Jun; 8(1):9-13. PubMed ID: 3725619
    [Abstract] [Full Text] [Related]

  • 6. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982 Jun; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 7. Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.
    Schettini F, Mautone A, Cavallo L, Altomare M, Montagna O, Dell'Edera L.
    Acta Haematol; 1981 Jun; 66(2):96-101. PubMed ID: 6794319
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R, Thévenin M, Bouveret JP, Jeannel F, Rymer JC.
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [Abstract] [Full Text] [Related]

  • 9. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E, Marcopito LF, Zago MA.
    Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
    [Abstract] [Full Text] [Related]

  • 10. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S, Cossu P, Toccafondi C, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Loi A, Bertolino F, Cao A.
    Am J Pediatr Hematol Oncol; 1983 Nov; 5(1):73-7. PubMed ID: 6859457
    [Abstract] [Full Text] [Related]

  • 11. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E.
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [Abstract] [Full Text] [Related]

  • 12. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 May; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 13. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 14. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C, Rachmilewitz EA.
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [Abstract] [Full Text] [Related]

  • 15. Response to long-term deferoxamine therapy in thalassemia.
    Cohen A, Martin M, Schwartz E.
    J Pediatr; 1981 Nov; 99(5):689-94. PubMed ID: 7299539
    [Abstract] [Full Text] [Related]

  • 16. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E, Bianco I, Graziani B, Lerone M, Valente M, Congedo P, Ponzini D, Costantini S.
    Acta Haematol; 1982 Nov; 68(2):115-23. PubMed ID: 6812366
    [Abstract] [Full Text] [Related]

  • 17. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 18. Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia.
    D'Angelo E, Mirra N, Rocca A, Carnelli V.
    J Pediatr Hematol Oncol; 2004 Jul; 26(7):451-3. PubMed ID: 15218422
    [Abstract] [Full Text] [Related]

  • 19. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M.
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [Abstract] [Full Text] [Related]

  • 20. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH, Markenson A, Miller DR, Chang H, Bestak M, Meyers P, Pisciotto P, Rifkind A.
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.